Streetbeat News

Analyst Ratings

AMT

Analysts have provided 12 ratings for American Tower (NYSE:AMT) over the past three months, with a mix of bullish and somewhat bullish sentiments. The average 12-month price target has increased by 6.4% to $239.58. American Tower's financial metrics, such as revenue growth and net margin, exceed industry averages, although its debt-to-equity ratio is higher, indicating financial risk.

Portfolio Pulse from Benzinga Insights

October 10, 2024 | 1:01 pm

TBLA

Analysts have mixed ratings for Taboola.com (NASDAQ:TBLA), with a recent decline in average price targets. The company's financial performance shows strong revenue growth but challenges in profitability and return on equity.

Portfolio Pulse from Benzinga Insights

October 10, 2024 | 1:01 pm

SWKS

Skyworks Solutions (NASDAQ:SWKS) has received mixed analyst ratings, with a recent average price target of $117.5, up from $103.92. Analysts have adjusted their ratings and price targets, reflecting varied expectations for the company's performance. Despite challenges in revenue growth and profitability, Skyworks maintains a balanced debt approach.

Portfolio Pulse from Benzinga Insights

October 10, 2024 | 1:01 pm

AMH

American Homes 4 Rent (NYSE:AMH) has been analyzed by 9 analysts, showing a range of perspectives from bullish to bearish. The average 12-month price target has increased by 7.92% to $42.22. Analysts have raised their ratings and price targets, indicating a positive outlook. The company has a strong market position with a market cap above industry standards, a net margin of 21.76%, and a debt-to-equity ratio of 0.71.

Portfolio Pulse from Benzinga Insights

October 10, 2024 | 1:00 pm

BIIB

Raymond James analyst Danielle Brill has reinstated a Market Perform rating on Biogen (NASDAQ:BIIB).

Portfolio Pulse from Benzinga Newsdesk

October 10, 2024 | 1:00 pm

CRUS

Barclays analyst Tom O'Malley has downgraded Cirrus Logic from Overweight to Equal-Weight and reduced the price target from $140 to $120.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2024 | 1:00 pm

ACAD

ACADIA Pharmaceuticals (NASDAQ:ACAD) has been analyzed by 7 analysts, showing a range of ratings from bullish to bearish. The average 12-month price target is $25.0, down from $29.43. Analysts have recently lowered their price targets, reflecting changing market conditions. Despite this, ACADIA shows strong financial performance with a 46.44% revenue growth rate, a net margin of 13.8%, and a low debt-to-equity ratio of 0.11.

Portfolio Pulse from Benzinga Insights

October 10, 2024 | 1:00 pm

ALGN

BLDR

IPX

OKUR

SITE

Top Wall Street analysts initiated coverage on several companies, including Align Technology, SiteOne Landscape Supply, OnKure Therapeutics, IperionX Limited, and Builders FirstSource. Notably, Builders FirstSource received a Buy rating from Goldman Sachs with a price target of $225.

Portfolio Pulse from Avi Kapoor

October 10, 2024 | 1:00 pm

SAGE

Raymond James analyst Danielle Brill has reinstated a Market Perform rating on Sage Therapeutics (NASDAQ:SAGE).

Portfolio Pulse from Benzinga Newsdesk

October 10, 2024 | 12:59 pm

VRTX

Raymond James analyst Danielle Brill has reinstated a Market Perform rating on Vertex Pharmaceuticals (NASDAQ:VRTX).

Portfolio Pulse from Benzinga Newsdesk

October 10, 2024 | 12:58 pm